Pharma Journalist -

Kite, a Gilead Company announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years…
Read More...

Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced on the 5th that the research results of their search for…
Read More...

InnoCare Pharma announced that BTK inhibitor orelabrutinib has been granted priority review for the treatment of relapsed or refractory Marginal Zone Lymphoma (R/R MZL) by the Center…
Read More...

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration…
Read More...

CARsgen Therapeutics Holdings Limited announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North…
Read More...

Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked patients, announced that the…
Read More...

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) approved expanded use of ORKAMBI (lumacaftor/ivacaftor) to include children with cystic…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with…
Read More...

Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, announces that the US Food and…
Read More...

Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.…
Read More...